Comparative Pharmacology
Head-to-head clinical analysis: LUMIGAN versus TRAVOPROST.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUMIGAN versus TRAVOPROST.
LUMIGAN vs TRAVOPROST
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bimatoprost is a prostamide analog that selectively mimics the effects of prostamide F2α, activating prostaglandin F (FP) receptors. It increases aqueous humor outflow through the uveoscleral pathway and may also enhance trabecular outflow, reducing intraocular pressure.
Travoprost is a synthetic prostaglandin F2α analog that acts as a selective FP receptor agonist. By binding to FP prostanoid receptors, it increases uveoscleral outflow of aqueous humor, reducing intraocular pressure.
One drop of 0.01% ophthalmic solution in the affected eye(s) once daily in the evening.
One drop of 0.004% ophthalmic solution in the affected eye(s) once daily in the evening.
None Documented
None Documented
Clinical Note
moderatePirlindole + Travoprost
"Pirlindole may increase the hypotensive activities of Travoprost."
Clinical Note
moderateTiaprofenic acid + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Travoprost
"The therapeutic efficacy of Travoprost can be decreased when used in combination with Carprofen."
Clinical Note
moderateBosentan + Travoprost
Terminal elimination half-life is approximately 78 minutes (range 54-102 minutes) in plasma after ocular administration. This short half-life reflects rapid systemic clearance, but ocular tissue levels persist longer due to local tissue binding.
Terminal elimination half-life is approximately 45 minutes (range 17–86 minutes) for travoprost free acid in plasma; clinical effect (IOP reduction) persists longer due to prolonged receptor binding.
Primarily via renal elimination (approximately 67% of administered dose excreted in urine as metabolites, with less than 1% as unchanged drug). The remainder is excreted in feces (approx. 25%) via biliary elimination.
Renal (approximately 20% as unchanged drug and free acid metabolites); biliary/fecal (about 60% as metabolites)
Category C
Category C
Prostaglandin Analog
Prostaglandin Analog
"Bosentan may increase the hypotensive activities of Travoprost."